5-LOX inhibitor modulates the inflammatory responses provoked by Helicobacter pylori infection

Helicobacter

Volumn 12, Issue 1, 2007, Pages 49-58

  Park, Soojin ^a   Han, Sang Uk ^a   Lee, Kee Myung ^a   Park, Kyung Ha ^a   Cho, Sung Won ^a   Hahm, Ki Baik ^b  

^a Ajou University School of Medicine   (South Korea)

^b Bundang Jesaeng Hospital   (South Korea)

Author keywords

5S HETE; Arachidonic acid; cPLA2; Geraniin; Helicobacter pylori; IL 8; Lipoxygenase; NDGA; NF B; TNF

Indexed keywords

GERANIIN; HYDROXYICOSATETRAENOIC ACID; INTERLEUKIN 8; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; NORDIHYDROGUAIARETIC ACID; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; EPITHELIUM CELL; FATTY ACID SYNTHESIS; GENE EXPRESSION REGULATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; INFLAMMATION; MACROPHAGE; MEDIATOR RELEASE; METABOLITE; MOUSE; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; STOMACH EPITHELIUM; WESTERN BLOTTING;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; CELL LINE; DOWN-REGULATION; EPITHELIAL CELLS; GLUCOSIDES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROLYZABLE TANNINS; INTERLEUKIN-8; LIPOXYGENASE INHIBITORS; MACROPHAGES; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; NORDIHYDROGUAIARETIC ACID; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

HELICOBACTER PYLORI;

EID: 33846217715     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00469.x     Document Type: Article

References (44)

1. Rothenbacher D, Brenner H. Helicobacter pylori and gastric cancer. Gastroenterology 2004;126:1927-8.
2. Scheiman JM, Cutler AF. Helicobacter pylori and gastric cancer. Am J Med 1999;106:222-6.
3. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997;113:1983-91.
4. Stoicov C, Saffari R, Cai X, et al. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 2004;341:1-17.
5. Dhar SK, Soni RK, Das BK, et al. Molecular mechanism of action of major Helicobacter pylori virulence factors. Mol Cell Biochem 2003;253:207-15.
6. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004;4:688-94.
7. 2) regulation of arachidonic acid mobilization. FEBS Lett 2002;531:2-6.
8. 2 activation. J Leukoc Biol 1999;65:330-6.
9. 2. Prostaglandins Leukot Essent Fatty Acids 2004;70:373-6.
10. Tanigawa T, Watanabe T, Hamaguchi M, et al. Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2. Am J Physiol Gastrointest Liver Physiol 2004;86:G148-56.
11. Takahashi M, Katayama Y, Takada H, et al. The effect of NSAIDs and a COX-2 specific inhibitor on Helicobacter pylori-induced PGE2 and HGF in human gastric fibroblasts. Aliment Pharmacol Ther 2000;14 (Suppl. 1):44-9.
12. 2) in epithelial cells. J Biol Chem 2001;276:804-10.
13. Ahmed A, Holton J, Vaira D, et al. Eicosanoid synthesis and Helicobacter pylori associated gastritis: increase in leukotriene C4 generation associated with H. pylori colonization. Prostaglandins 1992;44:75-86.
14. O'Connor JH. Eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6 (Suppl. 1):S113-9.
15. Ulmer HJ, Beckerling A, Gatz G. Recent use of proton pump inhibitor-based triple therapies for the eradication of H. pylori: a broad data review. Helicobacter 2003;8:95-104.
16. Bahr T, Schaper U, Becker K, et al. Influence of inhibitors of the eicosanoid metabolism, of antagonists of the eicosanoids and of PAF on mortality assayed in three biochemically characterized shock models. Biomed Biochim Acta 1988;47:S289-92.
17. Ikemoto S, Sugimura K, Kuratukuri K, et al. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2). Anticancer Res 2004;24:733-6.
18. Fujiki H, Suganuma M, Kurusu M, et al. New TNF-alpha releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutat Res 2003;523:119-25.
19. Okabe S, Suganuma M, Imayoshi Y, et al. New TNF-alpha releasing inhibitors, geraniin and corilagin, in leaves of Acer nikoense, Megusurino-ki. Biol Pharm Bull 2001;24:1145-8.
20. Yanagawa Y, Yamamoto Y, Hara Y, et al. A combination effect of epigallocatechin gallate, a major compound of green tea catechins, with antibiotics on Helicobacter pylori growth in vitro. Curr Microbiol 2003;47:244-9.
21. Fujiki H, Suganuma M, Okabe S, et al. Involvement of TNF-alpha changes in human cancer development, prevention and palliative care. Mech Ageing Dev 2002;123:1655-63.
22. Lee KM, Yeo M, Choue JS, et al. Protective mechanism of epigallocatechin-3-gallate against Helicobacter pylori-induced gastric epithelial cytotoxicity via the blockage of TLR-4 signaling. Helicobacter 2004;9:632-42.
23. Wescott JY, Balazy M, Stenmark KR, et al. Analysis of leukotriene D4 in human lung lavage by HPLC, RIA and mass spectrometry. Adv Prostaglandin Thromboxane Leukot Res 1986;16:353-61.
24. Fiorucci S, Meli R, Bucci M, et al. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in antiinflammatory therapy? Biochem Pharmacol 2001;62:1433-8.
25. Shureiqi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 2001;61:6307-12.
26. Leval X, Julemont F, Delarge J, et al. New trends in dual 5-LOX/ COX inhibition. Curr Med Chem 2002;9:941-62.
27. Nie D, Honn KV. Eicosanoid regulation of angiogenesis in tumors. Semin Thromb Hemost 2004;30:119-25.
28. Ding XZ, Iversen P, Cluck MW, et al. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 1999;61:218-23.
29. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997;235:418-23.
30. Poff CD, Balazy M. Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. Curr Drug Targets Inflamm Allergy 2004;3:19-33.
31. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-840.
32. Wallace JM. Nutritional and botanical modulation of the inflammatory cascade - eicosanoids, cyclooxygenases, and lipoxygenases - as an adjunct in cancer therapy. Integr Cancer Ther 2002;1:7-37.
33. Neuhouser ML, Patterson RE, Thornquist MD, et al. Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). Cancer Epidemiol Biomarkers Prev 2003;12:350-8.
34. Wargovich MJ. Colon cancer chemoprevention with ginseng and other botanicals. J Korean Med Sci 2001;16 (Suppl.):S81-6.
35. Weisburger JH, Chung PL. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem Toxicol 2002;40:1145-54.
36. Foryst-Ludwig A, Neumann M, Schneider-Brachert W, et al. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Commun 2004;316:1065-72.
37. Mahady GB, Pendland SL, Yun G, et al. Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res 2002;22:4179-81.
38. Munzenmaier A, Lange C, Glocker E, et al. A secreted/shed product of Helicobacter pylori activates transcription factor nuclear factor-kappa B. J Immunol 1997;159:6140-7.
39. Matsubara S, Shibata H, Ishikawa F, et al. Suppression of Helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem Biophys Res Commun 2003;310:715-9.
40. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726-35.
41. Yeo M, Park HK, Lee KM, et al. Blockage of HSP 90 modulates Helicobacter pylori-induced IL-8 productions through the inactivation of transcriptional factors of AP-1 and NF-kappaB. Biochem Biophys Res Commun 2004;320:816-24.
42. Mitsuno Y, Yoshida H, Maeda S, et al. Helicobacter pylori induced transactivation of SRE and AP-1 through the ERK signalling pathway in gastric cancer cells. Gut 2001;49:18-22.
43. Bhattacharyya A, Pathak S, Datta S, et al. Mitogen-activated protein kinases and nuclear factor-kappaB regulate Helicobacter pylori-mediated interleukin-8 release from macrophages. Biochem J 2002;368:121-9.
44. Slomiany BL, Slomiany A. Role of ERK and p38 mitogen-activated protein kinase cascades in gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide. IUBMB Life 2001;51:315-20.